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Rationale Growth and development during adolescence may modify the respiratory and vascular 
differences seen among extremely preterm (EP) individuals in childhood and early adolescence. 
Objective To assess the trajectory of respiratory and cardiovascular outcomes at transition to 
adulthood in a national longitudinal cohort study of births before 26 weeks of gestation in the UK 
and Eire. 
Method 129 EP participants and 65 controls attended for a center-based evaluation at 19 years of 
age. Standardized measures of spirometry, haemodynamics, functional capacity and markers of 
inflammation were made in EP subjects with and without neonatal bronchopulmonary dysplasia 
(BPD) and term born controls, at 19 years of age and compared to previous assessments. 
Results   Compared to controls, the EP group were significantly impaired on all spirometric 
parameters (Mean FEV1 z score: -1.08 SD (95%CI: -1.40 to -0.77)) and had lower FeNO concentrations 
(13.9 vs. 24.4 ppb, p<0.001) despite a higher proportion with bronchodilator reversibility (27% vs. 
6%). The EP group had significantly impaired exercise capacity. All respiratory parameters were 
worse following neonatal BPD and respiratory function differences were similar at 11 and 19 years. 
Augmentation index (AIx) was 6% higher in the EP group and associated with increased total 
peripheral resistance (difference in means 96.4 (95%CI: 26.6, 166.2) dyne/s/cm-5) and elevation in 
central but not peripheral blood pressure. Central systolic and diastolic blood pressure increased 
more quickly over adolescence in the EP group compared to controls. 
Conclusions Clinicians should address both cardiovascular and respiratory risk in adult survivors of 







There are over 2400 births before 26 weeks each year in the UK and survival is increasing 1. Adult 
physicians are increasingly faced with people who were born prematurely and may have life-long 
consequences of their preterm birth and neonatal treatment.  Most reports of long-term outcomes 
have considered the excess neuro-morbidity manifest from childhood, but increasingly adult 
cardiorespiratory consequences following preterm birth are being recognized.  A high proportion of 
these individuals will have had neonatal bronchopulmonary dysplasia (BPD), defined as chronic 
oxygen-dependent lung disease persisting beyond 36 weeks post menstrual age, and associated with 
a complex mix of developmental arrest of lung development and tissue injury 2.  Significant deficits 
in lung function in school-age children born extremely premature have been documented, which 
may be associated with markers of increased cardiovascular risk 3.  
In a national cohort study of births before 26 weeks of gestation (extremely preterm; EP) from the 
British Isles during 1995 (the EPICure study), we identified a clinically significant 1.5 standard 
deviation deficit in forced expiratory volume in one second (FEV1) at 11 years of age, greatest in 
those with neonatal BPD, and a doubling in reported diagnosis of asthma 4.  We also found impaired 
cardiovascular health including significantly increased supine diastolic BP and, in a subset, increased 
aortic augmentation index, a measure of arterial pressure wave reflections which is associated with 
presence of cardiovascular risk factors in younger individuals 5 and independently related to future 
cardiovascular disease (CVD) events in older individuals 6,7. Moreover, the elevation in augmentation 
index correlated with the severity of lung impairment as assessed by FEV1 3. The presence of 
irreversible airflow obstruction of this degree in adults would meet spirometric criteria for chronic 
obstructive pulmonary disease (COPD) 8.  Whether the airflow obstruction in adults born EP 9 
represents damaged but quiescent airways, or the presence of an active inflammatory process which 
may progress, but also be tractable, remains a key unanswered question. 
Based on the knowledge that peak lung function is attained in early adulthood and that there 
appeared to be an intrinsic relationship between respiratory and vascular measures, we investigated 
whether development during adolescence had modified the respiratory and vascular differences 
seen among extremely preterm (EP) individuals earlier in childhood, whether the posited 







EPICure is a well characterized, geographically based, UK/Ireland national cohort born at or less than 
25 completed weeks of gestation between March and December 1995.  Cardio-respiratory outcomes 
have been reported for this cohort at 11 years of age 3,4,10 and respiratory outcomes and seated 
brachial blood pressure at 6 years11,12.   
The 307 young adults from the original EPICure study cohort who were alive at 16 years were 
contacted and individual consent was obtained to continue on the study. All responders were invited 
to participate in the following assessments at 19 years, alongside 153 term-born normal birthweight 
controls without neonatal illness recruited from classmates matched for sex and age, previously 
evaluated at 11 years, re-consented in the same way.  There were no exclusion criteria. 
Assessments 
Clinical respiratory and cardiovascular assessments were conducted as part of a two-day assessment 
at the University College London Hospitals Clinical Research Facility. Participants who requested 
home assessment undertook similar cardiovascular and respiratory evaluations, but not the full two-
day assessment.  Participants and parents completed questionnaires about health and relevant 
family information.  Evaluation was undertaken by a single pediatrician (JB) trained in the protocols 
used for the study and blinded to the results of previous investigations.  Participants were given a 
brief explanation of their results by the study pediatrician and any clinically significant results were 
communicated to their responsible primary care doctor in writing. 
Further details of the methodology used are given in the on line data supplement (address) 
Respiratory evaluations Fractional exhaled nitric oxide (FeNO; Bedfont NObreath®) levels were 
measured prior to baseline spirometry. A portable spirometer (Easy on-PC, New Diagnostic Design 
Medical Technologies, USA) was used to measure FEV1, mid-expiratory flow (FEF25-75) and forced vital 
capacity (FVC) and repeated after administering a bronchodilator (400mcg salbutamol via a spacer).  
Spirometry data were converted to z-scores adjusted for height, age, sex and ethnicity 2,13.  
Functional exercise capacity was assessed using a standardized incremental shuttle walk test 3,14. 
Cardiovascular evaluations Seated and supine BP were measured using an oscillometric 
sphygmomanometer (Omron 705 CP, Omron Corporation, Japan).  Radial artery waveforms 
recorded using a high fidelity tonometer, were transformed into a corresponding central (ascending 
aortic) waveform using pulse wave analysis and a generalised transfer function (SphygmoCor, AtCor 




corresponding to the systolic pressure resulting from ventricular ejection and that resulting from 
return of the reflected pressure wave to the ascending aorta, respectively. Central SBP (the overall 
peak systolic pressure), pulse pressure (PP) and heart rate were then determined. Central 
augmentation pressure (AP) was calculated as the difference between the second and first systolic 
peaks; augmentation index (AIx) as the AP expressed as percentage of the central PP; while non-
augmented systolic pressure corresponded to the first systolic peak of the central waveform, thus 
indicating the influence of cardiac ejection characteristics on systolic pressure in the ascending 
aorta.  
Aortic pulse wave velocity (aPWV) was calculated from recordings at the carotid and femoral 
arteries, using the same device.  AIx data were converted to z-scores adjusted for age, height, MAP 
and heart rate 15.  Cardiac output and stroke volume were measured using a non-invasive 
bioreactance technique (NICOM, Cheetah Medical, USA) that has been validated against invasive 
gold standard techniques 16.   
Anthropometry and Physical Examination Height without footwear and weight were measured 
using standardized equipment.   
Biological Fasting blood and urine samples were processed at an on-site pathology laboratory to 
measure serum CRP and creatinine, and urine albumin:creatinine ratio using a standard, automated 
laboratory analyser, with calculation of estimated glomerular filtration rate (eGFR) using the four-
variable MDRD equation.  Plasma desmosine levels as a marker of elastin turnover were measured 
from stored frozen samples using liquid chromatography with mass spectrometry 4,17.  
Data management and statistical analysis  
Data were encoded for computer analysis using double entry and checked for outliers before 
combination with the main study dataset for analysis.  Electronic data from SphygmoCor, NICOM 
and Easy on-PC were extracted and merged with the database to avoid transcription errors.  Data 
were verified for accuracy and analyzed using Stata SE, version 15.1 (Stata Corp, College Station, 
Texas, USA).   
Mean values and standard deviations of parameters were calculated and unadjusted/adjusted mean 
differences with 95% confidence intervals (CIs) using linear regression models were reported for the 
EP and control groups and for EP participants with and without BPD.  Trajectories of lung and 
cardiovascular function from childhood to early adulthood were investigated using multilevel 
modelling, treating the data as having a hierarchical structure with observations at each time point 





The study was approved by the South Central Hampshire Health Research Authority Committee 
(UK).  Written informed consent was obtained from study participants, or in the case of those with 
severe learning difficulties, assent was provided by appointed consultees, according to the UK 
Mental Capacity Act 2005. 
Results 
Of 306 EP subjects known to be alive at 19 years, 129 attended for evaluation, 59% of those 
evaluated at 11 years of age (see online supplement Table E1).  Those assessed were representative 
of the whole cohort, with similar distributions of gestational age (mean 24.9 weeks) and birthweight 
(741g) but with lower birthweight for gestation (mean z-score: -0.21) compared to the whole cohort 
(24.9 weeks, 747 g and -0.18, respectively).  Similar proportions were receiving oxygen at 36 weeks 
postmenstrual age (72% v 74%) and had received steroids for weaning from neonatal ventilation 
(76% v 73%).  Compared to the cohort evaluated at 11 years, participants assessed at 19 years of age 
had lower birthweight for gestation but similar distributions of gestational age and proportions 
receiving oxygen at 36 weeks postmenstrual age and postnatal steroids (Table E1).  Participants aged 
19 also had similar distributions of baseline and post-bronchodilator FEV1 z-scores, blood pressure 
and adjusted AIx at 11 years, but had a slightly higher proportion with a diagnosis of asthma at 11 
years (29% v 25%). 
Of the 129 EP participants, 127 completed the cardiovascular and 123 the respiratory protocol.  111 
consented to venesection.  Of the control group, 65/153 controls seen at 11 years attended for 
evaluation, 64 completed the cardiorespiratory evaluation and 61 consented to venesection.  
Respiratory outcomes at 19 years:   Compared to controls, the EP group were significantly impaired 
on all spirometric parameters (Table 1).  The difference in mean post-bronchodilator FVC z-score 
between EP and control subjects was -0.64SD (95%CI: -0.94 to -0.35), equivalent to 470ml, and the 
mean difference in FEV1 z-scores was -1.08 SD (95%CI: -1.40 to -0.77), equivalent to 600ml.  
Bronchodilator reversibility (defined as >12% change in FEV1) was more common in the EP group 
(26.5%) compared to controls (6.3%; odds ratio: 5.39 (95%CI: 1.81, 16.04)), but the EP group were 
not significantly more likely to have had a former clinical diagnosis18 of asthma 41% vs. 34% (made 
by the participant’s usual clinician, and as reported by the participant).  19% of the EP group had 
irreversible airflow obstruction (FEV1/VC<LLN) at age 19, the same proportion as at age 11.  The EP 
group had significantly lower FeNO concentrations compared to controls (13.9 vs. 24.4 ppb, 
p<0.001) and significantly more control participants had a FeNO concentration above the threshold 




presence of bronchodilator reversibility, EP status remained associated with significantly lower FeNO 
(adjusted difference in means: -10.3 (95%CI -15.9, -4.7; p<0.001). 
There was no difference in post-bronchodilator FVC between the EP group with and without BPD, 
but the mean difference in FEV1 z-scores was -0.66 SD (95%CI: -1.06 to -0.27), equivalent to 280ml 
(Fig 1A).  Bronchodilator reversibility in those with neonatal BPD (33%) was more common than in 
those without (11%; p<0.05; Fig 1B).  A prior clinical diagnosis of asthma was more common in the 
EP group with neonatal BPD compared to those without (odds ratio: 3.80 (95%CI: 1.49, 9.57)), but 
there was no difference in FeNO between these two groups.  
Blood pressure and hemodynamic parameters at 19 years:  Whilst there were no significant 
differences in peripheral blood pressure in the EP group compared to controls (Table 2), calculated 
central blood pressures were significantly higher among EP participants by 4.5mmHg (systolic) and 
3.6mmHg (diastolic).  Cardiac output did not differ significantly between groups but stroke volume 
was significantly lower in the EP group, allied to a higher heart rate, even after adjusting for 
differences in body size.   
Total peripheral vascular resistance was significantly higher in the EP group (difference in means 
96.4 (95%CI: 26.6, 166.2) dyne/s/cm-5).  Aortic augmentation pressure was on average 2.0mmHg 
higher and augmentation index (Aix) 6% higher in the EP group, being of a similar order to that 
found in at 11 years (4.9% (95%CI: 2.0, 7.8)).   
In contrast to the respiratory findings, there were no consistent differences between the 
cardiovascular measures in the EP group who did and did not have neonatal BPD. 
Relationships between cardiovascular and respiratory parameters age 19: In multiple regression 
analysis, aortic AIx was significantly associated with EP and BPD status, but not independently with 
FEV1 or FVC (Table 3).  AIx was also significantly lower among EP participants with bronchodilator 
reversibility (mean AIx: 2.8% (sd: 10.4)) compared to those without reversibility (7.9% (8.2), p=0.004; 
difference in means after adjustment for covariates: -6.0% (95%CI: -9.8 to -2.1); p=0.003). 
Trajectory between 11 and 19 years  
Post-bronchodilator FEV1: changes in mean (SEM) FEV1 z-scores are illustrated in Figure 2A. The data 
show a slight fall in measured values across all groups, but no evidence of ‘catch up’ by EP 
participants.  Multilevel modelling indicated that on average, at 19 years the FEV1 z-scores of EP 
participants with and without BPD were 1.71 SD (95% CI: -1.95 to -1.47, p<0.001) and 0.92 SD (95% 




Blood pressure and hemodynamic parameters: Observed mean AIx values declined across 
adolescence in both EP children and controls.  Multilevel modelling indicated that these trajectories 
did not differ significantly and that overall the decline over time was not statistically significant (95% 
CI: -0.42 to 0.02, p=0.07; Fig 2B. In contrast, seated brachial systolic and diastolic blood pressure 
rose over time (Fig 2C), as did calculated central pressures (Fig 2D).  Multilevel modelling indicated 
that trajectories were similar in both groups: an average of 2.26 mmHg increase per year for seated 
SBP (95% CI: 2.12 to 2.39), 1.09 mmHg for seated DBP (95% CI: 0.97 to 1.20), 0.84 mmHg for central 
SBP (95% CI: 0.64 to 1.03), and 0.41 mmHg for central DBP (95% CI: 0.23 to 0.59). The observed 
difference in mean central SBP and DBP between EP children and controls increased between 11 and 
19 years, but estimates from multilevel modelling showed that differences in means between the 
two groups remained constant from 11 to 19 years: systolic of 3.34 mmHg (95% CI: 1.53 to 5.15, 
p<0.001) and diastolic 3.21 mmHg (95% CI: 1.56 to 4.87, p<0.001). 
Circulating biomarkers: Compared with controls, desmosine and creatinine concentrations were 
significantly higher in the EP group (Table E2), but there were no differences within in the EP group 
by BPD status.  There were no significant relationships between desmosine and FEV1 z-score, or 
aortic or radial AIx.  Whilst there was no difference in the mean estimated glomerular filtration rate 
(eGFR) or albumin:creatinine ratio between the groups, in multiple regression, aortic AIx was 
associated with both eGFR (p<0.007) and EP status (with BPD: p<0.001; without BPD: p=0.005), and 
aortic Pulse Wave Velocity was associated with eGFR (p=0.007; Table E3). 
Functional Capacity: There was a clinically and statistically significant lower shuttle walk distance in 
the EP group compared to the controls (899m (sd 305) vs. 1132m (303), p<0.05), and between the 
EP group with and without BPD (862m (304) vs. 991m (290), p<0.05; Table E4). 
 
Discussion: 
In this study, at 19 years respiratory function following birth before 26 weeks of gestation was 
characterized by clinically significant impairment of lung function across a range of spirometric 
parameters, before and following bronchodilator, and associated with a reduction in exercise 
capacity. The lung function deficits were of a similar magnitude to those seen at 11 years and there 
was no evidence of ‘catch up’ growth over adolescence. Indeed, data from the same cohort at 6 
years had already identified deficits in peak expiratory flow rates compared to controls of 1.2SD 
(95% CI: 1.4 to 0.8) for individuals with neonatal BPD and of 0.7SD (95% CI: 1.0 to 0.3) for those 
without.12  There was no evidence of on-going steroid-sensitive inflammation in the lung as assessed 




group.  The EP group had elevated markers of cardiovascular risk compared to controls, including 
higher blood and augmentation pressures. We believe that these differences are significant, for 
example the AIx differences equate to 10-15 years of arterial age 5.  
Our data argue against ‘catch-up’ lung growth in the EP group.  A systematic review conducted to 
2010 concluded that adult EP survivors with neonatal BPD had more respiratory symptoms and 
pulmonary function abnormalities compared with controls, and that this was associated with both 
radiologic structural changes and the suggestion of impairment in exercise capacity 20.  Some studies 
have reported ‘catch-up’ growth, postulating neo-alveolarization throughout childhood and 
adolescence 21, whilst others have detected accelerated decline 22 while others show stable 
differences from controls 9.  These differences may reflect different populations by birth weight and 
gestational age, improvements in neonatal treatment (‘old’ versus ‘new’ BPD), different follow-up 
ages and methods of testing, generally small sample sizes and the varying nature of control groups, 
all of which create a complex picture 23.  We have used the same techniques and standards to assess 
z-scores of function measures at both ages to minimize methodological errors. Conflicting findings 
are challenging for neonatologists wishing to make predictions about future lung health, and to 
adult physicians trying to manage individual patients.  These results suggest that one measure of 
lung function at age 11 or 19 is sufficient to identify participants with irreversible airflow 
obstruction. 
Relationships between small lungs and elevated cardiovascular risk are well described 24.  At age 6 
years, we identified significantly reduced lung function but normal seated brachial blood pressure BP 
in this cohort, compared to term-born classmates 11,12.  At age 11, when we measured central 
augmentation pressure for the first time, we found increased AIx in EP survivors compared to 
controls, and that these abnormal large-vessel hemodynamic changes were not reflected in 
measurements of seated peripheral BP 3.  Relationships between EP status and cardiovascular 
function persist in this new evaluation at 19 years, but significant differences between the EP and 
control groups are still not evident in peripheral blood pressure, whereas our central blood pressure 
and augmentation pressure data show significant differences.  At 11 years we postulated that 
augmentation pressure differences represented alterations in the smaller pre-resistance and 
resistance vessels and confirm this here, consistent with described alterations in the pulmonary 
arteries following neonatal BPD 25. Further work is required to understand the mechanisms of 
hypertension following EP birth in order to manage this optimally.  It is recognized that elevations in 
blood pressure in young adults track with hypertension in later life 26. 
The mechanisms of the respiratory and cardiovascular impairment observed at age 19 are complex, 




environment 27.  An important unanswered question was whether there is evidence of an active, 
tractable inflammatory process in the lungs.  Consequent to impaired respiratory health, with 
episodes of childhood wheeze, many EP survivors acquire a diagnosis of asthma and we continue to 
see a higher prevalence of an asthma diagnosis and treatments in the EP group with neonatal BPD, 
as reported by others 28.  Asthma can be a challenging diagnosis to make or exclude, and more 
recent guidelines – though controversial – have focused on FeNO 19.  FeNO concentration was 
independently lower in the EP group compared to the controls, even correcting for height. We do 
report an increase in the proportion of subjects with bronchodilator reversibility in the EP group 
compared to the controls, highest in the EP group with BPD.  If EP survivors have an accelerated 
decline in lung function, or indeed a normal decline rate from sub-maximal lung development, a 
proportion of the EP group will subsequently meet spirometric criteria for chronic obstructive 
pulmonary disease (COPD; post-bronchodilator FEV1/FVC below the lower limit of normal 8).  This 
poses a risk of misdiagnosis and potential over treatment for a second chronic respiratory condition.  
It is now recognized that individuals may reach spirometric definitions of COPD through multiple 
mechanisms including normal versus impaired maximal lung capacity, with accelerated or normal 
subsequent lung function decline 29.  In this group, we have recently reported that the EP 
microbiome shows significant dysbiosis in the airway regardless of neonatal BPD status 30, 
characterized by a shift in bacterial community composition away from Bacteroidetes as is typical in 
adults living with other chronic lung diseases including asthma and COPD 31. 
We report higher desmosine concentrations in the EP group compared to the controls.  Desmosine is 
an elastin breakdown product, the largest pool of which lies within the cardiovascular system. There 
is also significant elastin within the lung and elevated desmosine concentrations in chronic lung 
disease may relate to increased cardiovascular risk 32.  Elevated desmosine concentration may 
suggest an active process within large elastic arteries, although we did not identify a significant 
relationship between desmosine and either AIx or pulse wave velocity.  Alternatively, if the elevation 
in desmosine reflects on-going elastin turnover in the lung, this would argue against the hypothesis 
that adult lungs from EP survivors have ‘burnt out’ lung disease that does not require therapy to 
prevent further progression.  The elevation in desmosine, suggesting increased elastin turnover, 
requires further study. 
There is evidence for poor consideration of early-life factors amongst adult physicians 33.  It is 
notable that at age 19, whilst mean z-scores were lower, for many participants spirometry remained 
within the normal range. This may provide false reassurance to clinicians unfamiliar with the adult 
respiratory consequences of being born EP – abnormalities may only become apparent on exercise 




bronchodilator FEV1 and FVC but not z-scores which implies that it is related to lung size rather than 
function. 
Our analysis has strengths and weaknesses.  EPICure is a national cohort that has been followed 
longitudinally.  As with all longitudinal cohorts there is significant attrition. We are reassured that 
the sample seen at 19 years remains representative of the whole cohort in terms of baseline 
perinatal variables and results from those evaluated at each age are similar to those from the overall 
cohort. We have used multilevel modelling to provide confidence that we have, insofar as is 
possible, a representative cohort.   All our assessments were performed to carefully developed 
standard operating procedures.  Although we would have liked to include further testing, we were 
had no resources to perform other useful techniques, such as diffusion capacity testing and invasive 
estimations of cardiac output/stroke volume.  However, we did see trends to reductions in measures 
for both spirometry and augmentation index over adolescence.  We used the same equipment to 
evaluate vascular parameters at each age but measurements at 19 years were made in a formal 
standardized clinic setting in contrast to often ad hoc arrangements at 11 years, when the 
assessments were carried out in a sample examined at school. Our findings reflect associations and 
we cannot infer causation.   
In conclusion, EP survivors aged 19, especially those who had BPD, have impaired lung capacity at 
the time of expected peak lung size, elevation in markers of cardiovascular risk, and in association 
with decreased exercise capacity.  There was no evidence of steroid-sensitive inflammation within 
the lung as assessed by FeNO, but we did find evidence of increased systemic elastin turnover.  
Relationships between lung and AIx suggests that strategies to protect the developing lung during 
the immediate neonatal, infant and early childhood periods can be expected to have long term 
benefits on cardiorespiratory health.  Our key clinical messages are to emphasize meticulous 
attention to maximizing lung health in the perinatal, neonatal and childhood periods, and careful 
assessment and management of respiratory and cardiovascular risk in young adult survivors of EP 
including promotion of a healthy lifestyle, including for example physical activity, weight 
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Mean ±SD [range] 
Controls 
(N=64) 
Mean ±SD [range] 
EP with BPD 
(N=87)  
Mean ±SD [range] 
EP no BPD 
(N=36) 
Mean ±SD [range] 
EP versus controls  
 (95% CI) 
BPD versus no BPD 
 (95% CI) 
Pre-Bronchodilator       
FEV1 (L) 
2.87 ±0.72 
[1.29 to 4.66] 
3.56 ±0.65 
[2.30 to 5.29] 
2.77 ±0.69 
[1.29 to 4.35] 
3.10 ±0.73 
[1.56 to 4.66] 
-0.69 (-0.90, -0.48) 
*** 




[-5.06 to 0.68] 
-0.29 ±0.89 
[-2.24 to 1.92] 
-1.83 ±1.17 
[-5.06 to 0.68] 
-1.05 ±0.99 
[-3.87 to 0.26] 
-1.31 (-1.64, -0.98) 
*** 




[1.31 to 6.09] 
4.25 ±0.87 
[2.35 to 6.09] 
3.68 ±0.87 
[1.31 to 5.55] 
3.79 ±0.93 
[2.20 to 6.09] 
-0.53 (-0.80, -0.27) 
*** 
-0.11 (-0.45, 0.24) 
FVC z-score 
-0.76 ±1.06 
[-4.45 to 1.59] 
-0.00 ±0.93 
[-2.24 to 1.82] 
-0.84 ±1.07 
[-4.45 to 1.59] 
-0.59 ±1.02 
[-2.84 to 0.87] 
-0.76 (-1.07, -0.45) 
*** 
-0.24 (-0.64, 0.15) 
FEV1/FVC % 
0.78 ±0.10 
[0.52 to 1.00] 
0.85 ±0.08 
[0.60 to 0.99] 
0.76 ±0.10 
[0.52 to 1.00] 
0.82 ±0.08 
[0.65 to 1.00] 
-0.07 (-0.10, -0.04) 
*** 




[-3.95 to 2.28] 
-0.42 ±1.13 
[-3.06 to 2.21] 
-1.57 ±1.21 
[-3.95 to 2.28] 
-0.75 ±1.14 
[-2.62 to 2.18] 
-0.91 (-1.28, -0.55) 
*** 




[0.58 to 6.71] 
3.88 ±1.09 
[1.56 to 6.95] 
2.41 ±0.97 
[0.58 to 6.71] 
3.14 ±0.98 
[1.18 to 6.01] 
-1.26 (-1.58, -0.94) 
*** 




[-5.21 to 1.75] 
-0.44 ±1.11 
[-2.64 to 2.08] 
-2.14 ±1.19 
[-5.21 to 1.75] 
-1.17 ±1.02 
[-3.66 to 0.91] 
-1.41 (-1.77, -1.05) 
*** 
-0.97 (-1.41, -0.53) 
*** 
Post Bronchodilator       
Oxygen Saturation %  
97.49 ±1.23 
[93.00 to 100.00] 
(n=120) 
97.80 ±1.16 
[94.00 to 100.00] 
(n=64) 
97.45 ±1.36 
[93.00 to 100.00] 
(n=86) 
97.59 ±0.82 
[96.00 to 99.00] 
(n=34) 




[1.47 to 4.90] 
(n=121) 
3.71 ±0.73 
[2.36 to 5.58] 
(n=64) 
3.04 ±0.68 
[1.47 to 4.63] 
(n=86) 
3.32 ±0.70 
[1.93 to 4.90] 
(n=35) 
-0.60 (-0.81, -0.38) 
*** 
-0.28 (-0.56, 0.00) 
* 
  post-FEV1 z-score 
-1.04 ±1.08 
[-4.29 to 1.13] 
(n=121) 
0.05 ±0.90 
[-2.08 to 2.37] 
(n=64) 
-1.23 ±1.12 
[-4.29 to 0.94] 
(n=86) 
-0.54 ±0.98 
[-2.72 to 0.88] 
(n=35) 
-1.08 (-1.40, -0.77) 
*** 
-0.66 (-1.06, -0.27) 
** 
Percentage change in FEV1  
8.83 ±7.98 
[-7.40 to 35.52] 
(n=121) 
4.34 ±5.59 
[-7.38 to 20.38] 
(n=64) 
9.60 ±7.50 
[-6.47 to 35.52] 
(n=86) 
6.93 ±8.87 
[-7.40 to 35.19] 
(n=35) 
4.49 (2.28, 6.69) 
*** 
2.66 (-0.19, 5.51) 
  change in FEV1 >12%  32/121 (26.5%) 4/64 (6.3%) 28/86 (32.6%) 4/35 (11.4%) 
5.39 (1.81, 16.04)+ 
** 




[2.00 to 6.19] 
(n=121) 
4.23 ±0.90 
[2.37 to 6.14] 
(n=64) 
3.74 ±0.82 
[2.00 to 5.39] 
(n=86) 
3.83 ±0.93 
[2.26 to 6.19] 
(n=35) 
-0.47 (-0.73, -0.21) 
*** 
-0.09 (-0.43, 0.25) 
  post-FVC z-score 
-0.68 ±0.96 
[-3.52 to 1.48] 
(n=121) 
-0.04 ±0.98 
[-2.30 to 2.16] 
(n=64) 
-0.74 ±0.94 
[-3.52 to 1.48] 
(n=86) 
-0.54 ±0.98 
[-2.72 to 0.88] 
(n=35) 
-0.64 (-0.94, -0.35) 
*** 
-0.19 (-0.58, 0.19) 
post-FEV1/FVC  
0.83 ±0.09 
[0.54 to 1.00] 
(n=121) 
0.88 ±0.07 
[0.67 to 1.00] 
(n=64) 
0.82 ±0.10 
[0.54 to 1.00] 
(n=86) 
0.87 ±0.07 
[0.69 to 1.00] 
(n=35) 
-0.05 (-0.08, -0.02) 
*** 
-0.06 (-0.09, -0.02) 
*** 
  post-FEV1/FVC z-score 
-0.56 ±1.27 
[-4.27 to 2.37] 
(n=121) 
0.15 ±1.06 
[-2.56 to 2.27] 
(n=64) 
-0.79 ±1.29 
[-4.27 to 2.37] 
(n=86) 
-0.00 ±1.03 
[-2.24 to 2.15] 
(n=35) 
-0.71 (-1.08, -0.35) 
*** 
-0.79 (-1.25, -0.33) 
*** 
post-FEF2575 (L/min) 3.29 ±1.12 4.47 ±1.18 3.10 ±1.14 3.76 ±0.94 -1.17 (-1.52, -0.83) -0.66 (-1.10, -0.22) 
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[0.73 to 7.19] 
(n=121) 
[2.06 to 7.22] 
(n=64) 
[0.73 to 7.19] 
(n=86) 
[1.48 to 6.73] 
(n=35) 
*** ** 
  post-FEF2575 z-score 
-1.03 ±1.23 
[-4.58 to 2.07] 
(n=121) 
0.16 ±1.06 
[-2.33 to 2.54] 
(n=64) 
-1.28 ±1.28 
[-4.58 to 2.07] 
(n=86) 
-0.44 ±0.85 
[-2.55 to 1.46] 
(n=35) 
-1.19 (-1.55, -0.84) 
*** 
-0.84 (-1.29, -0.39) 
*** 
Fractional expired Nitric Oxide (FeNO)      
FeNO (ppb)  
13.9 ±11.1 
[0.0 to 56.7] 
(n=117) 
24.4 ±24.7 
[0.0 to 133.7] 
(n=62) 
13.4 ±10.0 
[0.0 to 51.3] 
(n=83) 
15.2 ±13.5 
[0.0 to 56.7] 
(n=34) 
-10.47 (-15.77, -5.18) 
*** 
-1.77 (-8.64, 5.10) 
  FeNO >40ppb 6/117 (5.1%) 9/62 (14.5%) 3/83 (3.6%) 3/34 (8.8%) 0.32 (0.11, 0.94)+ * 0.39 (0.07, 2.02) + 
Clinical Symptoms (self-report questionnaire)      
Asthma diagnosis ever 50/121 (41.3%) 21/61 (34.3%) 43/87 (49.4%) 7/34 (20.6%) 1.34 (0.71, 2.54) + 
3.80 (1.49, 9.57) + 
** 
Symptoms in the last year 24/121 (19.8%) 17/62 (27.4%) 19/87 (21.8%) 5/34 (14.7%) 0.65 (0.32, 1.34) + 1.62 (0.55, 4.76) + 
Wheeze during or after exercise 32/121 (26.5%) 19/61 (31.2%) 25/87 (28.7%) 7/34 (20.6%) 0.79 (0.40, 1.56) + 1.56 (0.60, 4.03) + 
Treated in the last year for 
respiratory or chest problems 
16/121 (13.2%) 12/60 (20.0%) 13/87 (14.9%) 3/34 (8.8%) 0.61 (0.27, 1.39) + 1.82 (0.48, 6.82) + 
Currently using inhalers 28/126 (22.2%) 11/64 (17.2%) 24/90 (26.7%) 4/36 (11.1%) 1.38 (0.64, 2.98) + 2.91 (0.93,9.09) + 
Hospital admission for 
“breathing difficulties” (last 
12m) 
1/119 (0.8%) 1/62 (1.6%) 1/87 (1.2%) 0/32 (0.0%) 0.52 (0.03, 8.41) + - 
+OR (95% CI) was reported for categorical variables; ***p<0.001; **p<0.01; *p<0.05. 
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TABLE 2: Blood pressure and vascular evaluations in extremely preterm (EP) participants and full-term controls (C) at 19 years of age 
  












EP no BPD (N=36) 
Mean ±SD 
[range] 
EP – C: 
unadjusted  
 means (95% CI) 
EP – C:  
adjusted¶ 
 means (95% CI) 
Seated brachial blood pressure 
Systolic BP  mmHg 
119.5±10.1 
[93.7 to 149.0] 
117.9±9.8 
[99.3 to 152.3] 
119.3±10.1 
[93.7 to 140.7] 
120.0±10.4 
[99.0 to 149.0] 
1.6 (-1.4, 4.6) 0.7 (-1.9, 3.4) 
Diastolic BP mmHg 
73.2±7.9 
[54.7 to 97.7] 
71.6±6.0 
[58.0 to 93.7] 
73.7±8.3 
[54.7 to 97.7] 
72.1±6.6 
[54.7 to 90.7] 
1.6 (-0.6, 3.8) 1.6 (-0.6, 3.8) 
Supine brachial blood pressure 
Systolic BP  mmHg 
119.1±10.0 
[94.3 to 148.3] 
116.1±10.0 
[95.7 to 149.0] 
119.4±10.3 
[94.3 to 142.3] 
118.4±9.4 
[102.3 to 148.3] 
3.0 (0.0, 6.1)* 2.0 (-0.5, 4.5) 
Diastolic BP mmHg 
69.4±7.4 
[52.0 to 93.3] 
65.9±5.8 
[54.0 to 84.0] 
69.9±7.6 
[55.0 to 90.3] 
68.2±7.0 
[52.0 to 93.3] 
3.5 (1.4, 5.6)** 3.5 (1.4, 5.6)** 
Pulse pressure mmHg 
49.7±8.9 
[29.3 to 78.7] 
50.2±9.3 
[36.0 to 80.0] 
49.6±8.9 
[29.3 to 78.7] 
50.2±9.0 
[32.3 to 72.3] 
-0.4 (-3.2, 2.3) -1.5 (-3.6, 0.6) 
Central blood pressure 
Systolic BPa mmHg 
101.2±8.0 
[81.0 to 125.3] 
96.7±7.8 
[78.0 to 126.3] 
101.8±8.4 
[81.0 to 120.7] 
99.8±6.8 
[87.7 to 125.3] 
4.5 (2.1, 6.9)*** 3.9 (1.7, 6.1)*** 
Non-augmented SBPa  mmHg 
 99.0± 8.0 [79.3 
to 124.0] 
 96.5± 7.5 [79.7 
to 122.0] 
 99.5± 8.2 [79.3 
to 120.7]  
 97.9± 7.4 [85.0 
to 124.0] 
2.5 (0.2, 4.9)* 1.9 (-0.2, 4.0) 
Pulse pressurea mmHg 
30.6±6.3 
[15.0 to 53.3] 
29.7±5.9 
[21.0 to 50.0] 
30.6±6.4 
[15.0 to 53.3] 
30.7±6.3 
[17.0 to 49.3] 
0.9 (-1.0, 2.7) 0.2 (-1.3, 1.7) 
Mean Arterial BPa  mmHg 
84.9±7.5 
[69.3 to 109.3] 
80.8±6.5 
[66.0 to 105.3] 
85.4±7.8 
[69.3 to 107.0] 
83.5±6.6 
[70.0 to 109.3] 
4.1 (1.9, 6.2)*** 3.9 (1.7, 6.1)*** 
Heart rate a  bpm 
71.2±12.0 
[44.3 to 102.0] 
66.8±8.7 
[47.7 to 92.3] 
72.1±12.3 
[49.2 to 102.0] 
68.9±11.0 
[44.3 to 89.8] 
4.4 (1.1, 7.7)* 4.9 (1.7, 8.1)** 
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Hemodynamic measures 




[-5.0 to 11.0] 
0.2±2.5 
[-4.7 to 5.0] 
2.3±3.1 
[-3.3 to 11.0] 
1.9±2.9 
[-5.0 to 9.7] 
2.0 (1.1, 2.9)***  2.0 (1.2, 2.8)*** 
Aortic Augmentation Index a % 
6.6±9.0 
[-14.0 to 28.7] 
0.4±8.2 
[-14.0 to 20.3] 
6.9±9.3 
[-11.3 to 28.7] 
6.0±8.2 
[-14.0 to 24.7] 
6.2 (3.5, 8.8)*** 6.0 (3.5, 8.5)*** 
Aortic pulse wave velocity a m/s 
5.1±0.7 
[3.1 to 7.6] 
4.9±0.5 
[4.1 to 6.8] 
5.2±0.6 
[3.8 to 6.5] 
4.9±0.7 
[3.1 to 7.6] 
0.2 (-0.0, 0.3) -0.0 (-0.2, 0.1) 
Cardiac Output l/min 
7.3±1.7 
[3.4 to 19.2] 
7.7±1.6 
[3.7 to 11.1] 
7.5±1.8 
[3.4 to 19.2] 
6.9±1.3 
[3.9 to 9.5] 
-0.4 (-0.9, 0.1) -0.5 (-1.0,-0.0)* 
Cardiac index a l/min/m2 
4.4±0.9 
[2.2 to 12.0] 
4.3±0.7 
[2.4 to 5.3] 
4.4±1.0 
[2.5 to 12.0] 
4.2±0.7 
[2.2 to 5.4] 
0.0 (-0.2, 0.3) 0.0 (-0.2, 0.3) 
Stroke volume  ml 
99.9±23.1 
[46.5 to 173.4] 
113.6±25.8 
[52.0 to 170.6] 
100.4±23.8 
[53.6 to 173.4] 
98.8±21.4 
[46.5 to 146.9] 
-13.7 (-20.9, -6.4) 
*** 
-15.3 (-22.1, -8.6) 
*** 
Stroke Volume Index a  Ml/m2 
59.4±10.4 
[32.6 to 85.1] 
63.4±11.4 
[341.6 to 858.6] 
59.2±10.5 
[37.6 to 85.1] 
59.8±10.5 
[32.6 to 78.4] 
-4.0 (-7.3, -0.7)* 
-4.3 (-7.6, -1.1) 
** 





[339.9 to 2153.8] 
875.5±222.7 
[518.1 to 1773.0] 
956.2±224.9 
[339.9 to 2153.8] 
1011.3±255.7 






BPD: neonatal bronchopulmonary dysplasia; BP: blood pressure 
¶ Adjusted BP parameters, cardiac output, cardiac index, stroke volume, stroke volume index, and total peripheral resistance for sex; adjusted aortic augmentation 
pressure and aortic augmentation index for sex, HR, height, MAP; adjusted aortic pulse wave velocity for sex and MAP 
a EP with BPD: N=90; EP: N=126. b EP with BPD: N=89; EP: N=125. *p<0.05; **p<0.01; ***p<0.001.  
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TABLE 3: Multiple Regression with aortic augmentation index Aix as the dependent variables (all participants; n=174). 
 Aortic AIx- model 1 Aortic AIx - model 2 
 B(95%CI) p B(95%CI) p 
Post-bronchodilator FEV1     
FEV1 0.40 (-2.54, 3.33) 0.790 0.69 (-1.90, 3.29) 0.599 
EP without BPD (ref.=controls) 5.66 (1.68, 9.64) 0.006 5.69 (2.16, 9.21) 0.002 
EP with BPD (ref.=controls) 6.31 (2.64, 9.98) 0.001 7.4 (4.08, 10.72) <0.001 
Heart rate  (bpm) - - -0.41 (-0.53, -0.29) <0.001 
MAP (mmHg) - - 0.29 (0.11, 0.48) 0.002 
Post-bronchodilator FVC     
FVC -0.10 (-2.67, 2.47) 0.939 -0.12 (-2.41, 2.18) 0.921 
EP without BPD (ref.=controls) 5.51 (1.57, 9.45) 0.006 5.43 (1.93, 8.93) 0.003 
EP with BPD (ref.=controls) 6.02 (2.67, 9.37) 0.001 6.92 (3.85, 9.98) <0.001 
Heart rate  (bpm) - - -0.41 (-0.53, -0.29) <0.001 
MAP (mmHg) - - 0.29 (0.11, 0.48) 0.002 
Bronchodilator reversibility (> 12% change in FEV1)    
FEV1 reversible+ -5.58 (-8.96, -2.20) 0.001 -4.56 (-7.58, -1.54) 0.003 
EP without BPD (ref.=controls) 5.48 (1.73, 9.23) 0.004 5.42 (2.08, 8.76) 0.002 
EP with BPD (ref.=controls) 7.29 (4.12, 10.47) <0.001 7.93 (5.04, 10.83) <0.001 
Heart rate  (bpm) - - -0.39 (-0.51, -0.27) <0.001 
MAP (mmHg) - - 0.28 (0.10, 0.46) 0.002 
Variables entered in  
model 1: group variable (EP with BPD,  EP without BPD and controls), age at testing (years), height (cm), weight 
(kg), sex, ethnicity, regular exposure to smoking, and maternal smoking during pregnancy;  






LEGENDS FOR FIGURES: 
 
FIGURE 1: FEV1 z-score before (A) and percent change after bronchodilator (B) in term-born controls and extremely preterm participants (with and without 
neonatal bronchopulmonary dysplasia (BPD)) at 19 years of age. 
 
FIGURE 2: Trajectory of FEV1 and cardiovascular parameters in term-born controls and extremely preterm participants (with and without neonatal 
bronchopulmonary dysplasia (BPD)) through to 19 years of age. 
